MergerLinks Header Logo

Request Deal Involvement

Biocon Biologics completed the acquisition of the biosimilar assets of Viatris for $3.3bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Hogan Lovells

legal advisors

Hogan Lovells

Arthur Cox

legal advisors

Arthur Cox

Saraf & Partners

legal advisors

Saraf & Partners

AlixPartners

financial advisors

AlixPartners

Cravath Swaine & Moore

legal advisors

Cravath Swaine & Moore

PJT Partners

financial advisors

PJT Partners

PricewaterhouseCoopers

financial advisors

PricewaterhouseCoopers

Ernst & Young

financial advisors

Ernst & Young

Goodwin Procter

legal advisors

Goodwin Procter

Shardul Amarchand Mangaldas & Co

legal advisors

Shardul Amarchand Mangaldas & Co

Allegro Capital

financial advisors

Allegro Capital

K Law

legal advisors

K Law

Herbert Smith Freehills Kramer

legal advisors

Herbert Smith Freehills Kramer

or

Principals

VIATRIS (BIOSIMILARS ASSETS)

target

VIATRIS (BIOSIMILARS ASSETS)

VIATRIS

vendor

VIATRIS

BIOCON BIOLOGICS LTD

bidder

BIOCON BIOLOGICS LTD

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite